Nobili V, Vajro P, Dezsofi A, et al
At present, the compound is undergoing a phase III clinical trial (NCT03254446) to assess its effectiveness in mitigating cardiovascular risk in individuals with diabetes, dyslipidemia, and hypertension [76, 77]
Additionally, strong security measures are adhered to during the consent process to ensure patient data protection, including HIPAA compliance
Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis
Effects of high-frequency nanosecond pulses on prostate cancer cells
Notably, indoleamine 2,3-dioxygenase 1 (IDO1), a pivotal enzyme in tryptophan catabolism, drives immunosuppression by converting tryptophan to kynurenine (Kyn), thereby activating the aryl hydrocarbon receptor (AhR)